IN Brief:
- Permanent FDA authorisation covers Bubs Goat, Bubs 365 Day Grass Fed, and Bubs Essential infant formulas.
- Bubs says its products, manufacturing systems, and scientific evidence satisfy US safety, nutritional-adequacy, and quality requirements.
- Permanent access provides a firmer base for branded growth and possible private-label participation, subject to further approvals and commercial milestones.
Bubs Australia has secured permanent US Food and Drug Administration authorisation for three infant formula products, replacing the temporary regulatory pathway that supported its expansion into the United States after the 2022 formula shortage.
The authorisation covers Bubs Goat, Bubs 365 Day Grass Fed, and Bubs Essential. Bubs says the decision confirms that its products, manufacturing systems, and scientific evidence satisfy US regulatory requirements for safety, nutritional adequacy, and quality.
All three products are listed by the FDA among non-exempt infant formulas marketed in the United States. The agency also records Bubs as having submitted the required new infant formula documentation by the July 2025 deadline under the transition plan for manufacturers that had entered the market through enforcement discretion.
That transition plan followed emergency measures introduced in 2022 to increase US formula supplies. Manufacturers that received enforcement-discretion letters were allowed to continue selling while they worked towards the statutory and regulatory requirements applying to long-term participation in the US market.
Permanent status closes that temporary phase for Bubs. The company says it is now one of a limited group of non-US manufacturers authorised to supply the category and can pursue further branded growth from a firmer regulatory base.
The approval also gives greater certainty to the manufacturing operation behind the products. Bubs has built its US supply around its Deloraine canning facility in Victoria, where production capacity, quality systems, ingredient control, testing, and regulatory documentation have all been part of the company’s route towards permanent market access.
Infant formula is unusually demanding from a manufacturing-control perspective because the finished product may be the sole source of nutrition for a baby. Formula composition, nutrient levels, microbiological controls, ingredient specifications, environmental hygiene, packaging integrity, traceability, and release testing have to be managed within a regulatory framework that requires evidence before products can remain on the market.
Bubs’ authorisation therefore carries more weight than a conventional export registration. The company’s announcement explicitly links the decision to its manufacturing systems and scientific evidence, while the FDA’s current product list confirms that Bubs Goat, Bubs 365 Day Grass Fed, and Bubs Essential are recognised as non-exempt formulas marketed in the US.
The decision should also make capacity planning less speculative. Bubs says its products are already represented in more than 10,000 US stores, so permanent access provides a clearer basis for ingredient purchasing, packaging requirements, production campaigns, laboratory resources, and inventory planning than a temporary enforcement arrangement.
That certainty does not remove the operating risk. A larger established market increases the consequences of a quality failure, line interruption, ingredient shortage, or packaging problem because any disruption has to be managed across a broader retail network while the manufacturer remains inside a tightly supervised product category.
Change control becomes particularly important as the business grows. Alterations to formulations, ingredients, suppliers, packaging, or manufacturing processes have to be assessed against the approved product and supporting regulatory file before implementation, which ties procurement and production decisions closely to quality and regulatory teams.
Bubs also sees the approval as a platform for further product innovation and possible participation in the US private-label infant nutrition market. The company has been clear that any private-label expansion would remain subject to additional regulatory, technical, and commercial milestones, so the present authorisation does not automatically extend to future formulas.
That distinction matters because infant formula cannot be treated as a simple contract-packing category. A private-label customer would still require a compliant formulation, validated production route, appropriate evidence, agreed specifications, packaging controls, and the regulatory work needed for the finished product to be placed on the US market.
The permanent authorisation could nevertheless improve the utilisation case for Bubs’ Australian manufacturing assets if US volumes continue to rise. Formula plants carry substantial fixed costs across blending, canning, cleaning, maintenance, laboratory testing, validation, quality assurance, and technical staffing, making stable throughput important to unit economics.
Bubs plans to discuss the authorisation and its US strategy with investors on 10 September. Beyond that presentation, the operational indicators will be production volumes, retailer distribution, repeat orders, any additional formula submissions, and whether the company expands manufacturing output without weakening the controls that secured permanent access.
The regulatory milestone is now settled for the three named products. The next test is less bureaucratic and more industrial: converting permanent market access into sustained, compliant throughput at the Deloraine facility while maintaining the quality performance expected in one of food manufacturing’s most closely controlled categories.
